Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) research hub

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

This study looks at two medicines, ivosidenib and azacitidine, for a blood condition called myelodysplastic syndromes (MDS). It's for people with a specific gene change (IDH1 mutation) who haven't had certain treatments before. The aim is to see which medicine works best.